Abstract 14035: Clinical Outcomes Following Hospitalization for COVID-19 in Patients With Cardiac Sarcoidosis in the United States
Muzammil Farhan, Kamleshun Ramphul, Raheel Ahmed, Azeem Hassan, Ali Hasan, Hasan Ahmad, Joseph Okafor, Caleb Carver, Ayesha Jadoon, Khadija Amanullah, Yumna Jamil, Maham Bilal, Sajeel Ahmed, Rahat A Memon, Hemamalini Sakthivel- Physiology (medical)
- Cardiology and Cardiovascular Medicine
Background: Chronic immunosuppressive therapy and concomitant pulmonary involvement are two possible factors that could contribute towards adverse outcomes for patients with a history of Cardiac Sarcoidosis (CS) who are hospitalised with Covid-19. In this study, we aimed to identify co-morbidities and clinical outcomes for patients with CS post hospitalization for Covid-19.
Methods: Patients aged ≥18 years, with a positive diagnosis of COVID-19 (via ICD-10 code “U071”) between 1st April 2020 to 31st December 2020, were identified from National Inpatient Sample Database. Patients with CS were compared for patient characteristics, demographics and hospital-related outcomes against patients without CS using multivariable regression analysis.
Results: We identified a total of 1,608,285 cases of COVID-19 infection admitted to the hospital out of whom 60 patients were confirmed to have CS. CS patients were younger (mean 57.8 vs. 63.3 years, p<0.01), had a higher mean Charlson comorbidity index (CCI: 5.17 vs. 2.72, p<0.01) with greater prevalence of previous myocardial infarction (25.0% vs. 4.2%, p<0.01), atrial fibrillation (58.3% vs. 15.6%, p<0.01), smoking (50% vs. 26.1%, p<0.01), chronic kidney disease (66.7% vs. 20.6%, p<0.01) and diabetes (75.0% vs. 40.0%, p<0.01) as compared to patients without CS. Moreover, clinical outcomes of patients with CS were more adverse following hospitalization for COVID-19 including use of mechanical ventilation (25.0% vs. 11.2%, p<0.01, adjusted OR 1.39 95% CI: 1.37-1.41), acute kidney injury (50.0% vs. 28.2%, p<0.01, adjusted OR 1.86, 95% CI: 1.84-1.88) and death (25.0% vs. 13.1%, p<0.01, adjusted OR 3.15, 95% CI: 3.10- 3.20) (Table 1).
Conclusion: CS patients hospitalized for COVID- 19 infection had greater CCI and worse clinical outcomes such as mechanical ventilation use, acute kidney injury and death when compared to patients without cardiac sarcoidosis. Keywords: Cardiac sarcoidosis, COVID- 19, outcomes.